Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Journal of Clinical Oncology · 20.04.2025 · 43 (12) · 1453-1462
DOI: 10.1200/jco-24-02239 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2025. Verfasst von Mark M Awad und 18 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial. METHODS Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery. Analyses included event-free survival (EFS), OS, pathologic response, surgical outcomes, biomarker analyses, and safety. RESULTS A total of 221 patients were concurrently randomly assigned to nivolumab plus ipilimumab (n = 113) or chemotherapy (n = 108). At a median follow-up of 49.2 months, the median EFS was 54.8 months (95% CI, 24.4 to not reached [NR]) with nivolumab plus ipilimumab versus 20.9 months (95% CI, 14.2 to NR) with chemotherapy (HR, 0.77 [95% CI, 0.51 to 1.15]); 3-year EFS rates were 56% versus 44%. Higher rates of EFS events were initially seen, with later benefit favoring nivolumab plus ipilimumab; 3-year OS rates were 73% versus 61% (HR, 0.73 [95% CI, 0.47 to 1.14]); pathologic complete response rates were 20.4% versus 4.6%, respectively. In the respective arms, 83 (74%) and 82 patients (76%) underwent definitive surgery. Grade 3-4 treatment-related adverse events occurred in 14% and 36% of patients, respectively. CONCLUSION Neoadjuvant nivolumab plus ipilimumab showed potential long-term clinical benefit versus chemotherapy, despite early crossing of EFS curves in the preoperative phase and a lower rate of high-grade toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA.
- The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD.
- Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.
- McGill University Health Centre, Montreal, QC, Canada.
- Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Julie Brahmer, Gene B Saylors, Ke-Neng Chen, Jaclyn Neely, Mariano Provencio Pulla
Zitieren
APA
Awad, M. M., Forde, P. M., Girard, N., Spicer, J., Wang, C., Lu, S., Mitsudomi, T., Felip, E., Broderick, S. R., Swanson, S. J., Brahmer, J., Kerr, K., Saylors, G. B., Chen, K. N., Gharpure, V., Neely, J., Balli, D., Hu, N., & Provencio Pulla, M. (2025). Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. Journal of Clinical Oncology, 43(12), 1453-1462. https://doi.org/10.1200/jco-24-02239
Vancouver
Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, et al. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. Journal of Clinical Oncology. 2025;43(12):1453-1462. doi:10.1200/jco-24-02239
BibTeX
@article{Awad2025,
author = {Awad, Mark M and Forde, Patrick M and Girard, Nicolas and Spicer, Jonathan and Wang, Changli and Lu, Shun and Mitsudomi, Tetsuya and Felip, Enriqueta and Broderick, Stephen R and Swanson, Scott J and Brahmer, Julie and Kerr, Keith and Saylors, Gene B and Chen, Ke-Neng and Gharpure, Vishwanath and Neely, Jaclyn and Balli, David and Hu, Nan and Provencio Pulla, Mariano},
title = {Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {12},
pages = {1453--1462},
doi = {10.1200/jco-24-02239}
}
EUVIMED